Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Corgenix Cancels Genesis Bioventures Merger

By Labmedica staff writers
Posted on 08 Feb 2005
Due to a lack of progress toward the completion of the financing and the expiration dates on legal documents, Corgenix Medical Corp (Denver, CO, USA) has terminated its proposed U.S.$6 million merger with Genesis Bioventures (Surrey, Canada).

Corgenix develops and manufactures anti-phospholipid test kits, and its anticardiolipin (aCL) assay has been cleared by the U.S. More...
Food and Drug Administration (FDA). The company is focused on the development of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

"We regret that it was necessary to terminate the proposed merger after spending so much time and energy on it,” stated Douglass Simpson, president of Corgenix. "However, on the positive side, Corgenix is investigating a broad range of business opportunities, including the pursuit of our own equity financing.”





Related Links:
Corgenix
Genesis Bioventures

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.